Lv11
90 积分 2024-08-15 加入
1395 CLN 619 a clinical stage MICA B specific IgG1 antibody which restores the MICA B-NKG2D axis requires Fc function for potent anti-tumor activity
14天前
已完结
204 Combining FT536, a pan-tumor targeting CAR NK cell therapy, with CD16 engagers provides a coordinated targeting strategy to overcome tumor heterogeneity
15天前
已完结
Design of Remarkably Simple, Yet Potent Urea-Based Inhibitors of Glutamate Carboxypeptidase II (NAALADase)
21天前
已完结
The target atlas for antibody-drug conjugates across solid cancers
2个月前
已完结
Chinese innovative drug R&D trends in 2024
2个月前
已完结
Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands
3个月前
已完结
Development of [177Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression
3个月前
已完结
皖公网安备34019202002308
